It generally takes 10 to 12 years for a new pharmaceutical product to move from early-stage research to market. Can an optimized research process—including streamlined quality review with AI-powered workflow and process automation tools—help get breakthrough drugs to market faster?

During a recent “Pathology at Life Speed” session, Proscia Chief Product Officer Nathan Buchbinder and Dr. Dan Rudmann, Scientific Director, Digital Pathology at Charles River Labs, delivered several valuable insights:

The adoption of digital solutions that generate high magnification, high-detail images has generated an unprecedented volume of pathology data.

Artificial intelligence not only drives new insights via diagnostic assist and grading tools; process automation solutions also enable operational advantages that can accelerate research.

Automated quality control can reduce variability—and improve speed-to-market—by detecting artifacts before researchers incorporate whole slide images into their data sets.

“Improve Research Efficiency and Data Quality with AI-powered Workflow Automation” is essential viewing for life sciences research leaders. Watch it now.

About Proscia: Proscia’s mission is to transform cancer research and diagnosis with intelligent software that changes the way the world practices pathology. The company’s Concentriq® for Research digital pathology platform unifies multi-site teams, data, and applications to improve collaboration and unlock groundbreaking insights.